@article{3107102,
    title = "Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes",
    author = "Kattamis, A. and Aydinok, Y. and Taher, A.",
    journal = "European Journal of Haematology",
    year = "2018",
    volume = "101",
    number = "3",
    pages = "272-282",
    publisher = "Wiley-Blackwell Publishing Ltd",
    issn = "0902-4441, 1600-0609",
    doi = "10.1111/ejh.13111",
    keywords = "alanine aminotransferase;  creatinine;  deferasirox;  deferiprone;  deferoxamine;  deferasirox;  iron chelating agent, abdominal pain;  agranulocytosis;  arthralgia;  blood transfusion;  cancer survival;  creatinine blood level;  diarrhea;  dispersible tablet;  ferritin blood level;  gastrointestinal hemorrhage;  high frequency hearing loss;  human;  injection site reaction;  iron chelation;  iron overload;  iron storage;  liver toxicity;  low risk patient;  myelodysplastic syndrome;  nausea;  nephrotoxicity;  neutropenia;  palatability;  patient satisfaction;  priority journal;  proteinuria;  rash;  retinopathy;  Review;  side effect;  tablet formulation;  thalassemia;  treatment duration;  vomiting;  Yersinia infection;  blood transfusion;  chelation therapy;  complication;  disease management;  iron overload;  liver function test;  medication compliance;  myelodysplastic syndrome;  procedures;  thalassemia;  treatment outcome, Blood Transfusion;  Chelation Therapy;  Deferasirox;  Disease Management;  Humans;  Iron Chelating Agents;  Iron Overload;  Liver Function Tests;  Medication Adherence;  Myelodysplastic Syndromes;  Thalassemia;  Treatment Outcome",
    abstract = "Effective iron chelation therapy is an important part of treatment in patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes (MDS). Key strategies for optimising iron chelation therapy include ensuring good adherence and preventing and managing adverse events (AEs). Good adherence to iron chelation therapy with deferoxamine and deferasirox has been linked to improved survival and/or reductions in complications related to iron overload; however, maintaining good adherence to iron chelators can be challenging. Patients with transfusion-dependent thalassaemia or lower-risk MDS showed better adherence to the deferasirox film-coated tablet (FCT) formulation than to the deferasirox dispersible tablet formulation in the ECLIPSE trial, reflecting in part the improved palatability and convenience of deferasirox FCT. As well as affecting adherence, AEs may lead to dose reduction, interruption or discontinuation, resulting in suboptimal iron chelation therapy. Preventing and successfully managing AEs may help limit their impact on adherence, and following dosage and administration recommendations for iron chelators such as deferasirox may help minimise AEs and optimise treatment in patients with transfusion-dependent thalassaemia and lower-risk MDS. © 2018 The Authors. European Journal of Haematology Published by John Wiley & Sons Ltd."
}